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ncomplete Stent Apposition
hould We Appose or Oppose?*
ason B. Lindsey, MD, Steven P. Marso, MD
ansas City, Missouri
ncomplete stent apposition (ISA), also known as stent
alapposition, is defined most simplistically as the absence
f contact between stent struts and the vessel wall not
verlying a side branch. Incomplete stent apposition can
ccur at the time of stent implantation—acute ISA—which
ight either resolve or persist at follow-up (late-persistent
SA). Patients without ISA at the time of stent implanta-
ion but in whom ISA is detected at follow-up are deemed
o have late-acquired ISA. Stent underexpansion is defined as
he cross-sectional area (CSA) of the stent compared with
essel size, either measured as mean reference-lumen CSA
r lesion or reference-external elastic membrane CSA (1).
See page 486
stent lumen area of 5.0 to 5.5 mm2 on intravascular
ltrasound (IVUS) has been associated with stent throm-
osis (ST) and restenosis (2,3). The phenomenon of ISA is
nly detected by IVUS or optical coherence tomography
OCT), and there is no reliable angiographic surrogate. The
requency of acute ISA seems to be approximately 10% and
s similar between bare-metal stents (BMS) and drug-
luting stents (DES) (4). The mechanism underlying acute
SA seems to be related to procedural technique and is most
ikely due to suboptimal stent implantation or severely
alcified lesions, which do not allow for homogenous stent
xpansion (5). Late ISA is detected more often after DES
10% to 20%) than BMS (5% to 10%) implantation (5–7).
here are multiple postulated etiologies for late ISA,
ncluding unrecognized ISA at time of stent implantation
late-persistent ISA), but late ISA seems to be predomi-
ately caused by 2 mechanisms (6–8). First, after stent
mplantation there might be an increase in vessel volume
ith minimal or no change in plaque volume, so-called
ositive remodeling; this is in all likelihood the most
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
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arso is a consultant for Abbott Vascular, NovoNordisk, and The Medicinest
ompany, and has received research grants from Amylin Pharmaceuticals, Boston
cientific, The Medicines Company, Terumo Medical, and Volcano Corporation.ommon mechanism underlying late ISA. Second, throm-
us dissolution behind the stent might occur, which subse-
uently results in a gap between the stent and the vessel
all; this mechanism is most important after stent implan-
ation in acute coronary syndromes (8,9). Therefore, the
ressing questions are: Should we be concerned about ISA?
nd if so, should we be routinely screening for ISA? And if
o, who should do the screening? How should it be
anaged?
In this issue of JACC: Cardiovascular Interventions, Stein-
erg et al. (10) provide further insight into the clinical
mplications of ISA. Existing data regarding the outcomes
n patients with ISA are largely observational retrospective
tudies, and controversy exists regarding the clinical rami-
cations of ISA. Acute ISA has never been associated with
dverse events, and the preponderance of data regarding late
SA demonstrates no association with adverse cardiovascu-
ar events at follow-up (6–8,11,12). However, some inves-
igators have found that late ISA is associated with very late
T (9,13). Hoffmann et al. (6) reported pooled data from
everal sirolimus-eluting stent trials that showed that at
-year follow-up subjects with late ISA had a similar
ncidence of major adverse events when compared with
hose without late ISA, suggesting no influence of late ISA
n long-term clinical outcomes. These results are supported
y several other studies that also demonstrated no associa-
ion between late ISA and adverse clinical events, including
eath and ST (7,8,11,12). However, Cook et al. (9) evalu-
ted consecutive patients presenting with very late ST with
VUS and found that, compared with IVUS from control
ubjects without very late ST, there was significantly more
requent ISA (77% vs. 12%, p  0.001), suggesting that
SA might play a role in the pathogenesis of ST. A recently
ublished meta-analysis using data from randomized trials
ound that late ISA was associated with very late ST, which
eems to support the findings of Cook et al. (9). It is easy to
ee why so much controversy and contentious debate exist
bout the role of ISA in adverse events, specifically ST. So
hat are we to believe?
In the present study, Steinberg et al. (10) use pooled
VUS-substudy data from the several TAXUS trials to
nvestigate the role of both acute and late ISA and future
linical events over long-term follow-up of 2-years. Of the
,580 patients with IVUS studies both at stent implantation
nd at 9-month follow-up, there were 96 cases of acute ISA
6.0%) with no difference between BMS and DES and 36
ases of late ISA (2.7%) with more late ISA in the TAXUS
Boston Scientific, Natick, Massachusetts) moderate-release
tent group (not commercially available stent platform) than
MS. Although the acute ISA frequency and lack of
ifference between BMS and DES seen in the present study
re similar to previous reports (7,8,14), the rates of late ISA
re significantly lower and could be explained by the fact
hat acute ISA was treated at the time of implantation with
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496ost-dilation and therefore not allowed to present as late-
ersistent ISA at 9-month IVUS follow-up.
With regard to acute ISA, the authors found that it had
o impact on 9-month clinical events; this finding is
onsistent with all other previous reports (7,8,14) and
uggests that acute ISA likely has no impact on short-term
linical outcomes. However, the major limitation to this and
ther like-designed studies is the lack of power to discrim-
nate the risk of acute ISA.
Turning to the phenomenon of late ISA, the investigators
ound that during the 2-year clinical follow-up after the
cheduled 9-month IVUS follow-up, major adverse cardiovas-
ular events were comparable among patients with and those
ithout late ISA. Again, these data are concordant with most
revious studies investigating late ISA (6–8,11,12,14). In
ddition, the authors found that the late ISA seemed to result
rom positive remodeling without concomitant proportional
bluminal neointimal growth, which is also consistent with
umerous previous studies (6–8,11,12,14,15). The authors
onclude that, on the basis of their findings, neither routinely
etected acute ISA nor routinely detected late ISA is associated
ith adverse clinical events over long-term follow-up.
Steinberg et al. (10) should be commended on a well-
erformed analysis that provides additional information to the
urrent body of literature evaluating ISA.However, as with any
tudy there are limitations that we should consider before
aking definitive statements regarding ISA. First, the number
f late ISA cases is small (n  36) within this relatively large
ollection of pooled IVUS substudy patients, and therefore the
umber of cardiovascular events was exceedingly low, in fact no
T occurred in any patient with late ISA. Inadequate power is
n important weakness of not just the present study by
teinberg et al. but all studies to date that have attempted to
xamine the clinical importance of ISA. It is exceedingly
ifficult to demonstrate an association between a relatively
ncommon occurrence (late ISA) and an even rarer event such
s very late ST. Second, the authors do not report the mean
SA area, which is important in understanding the severity of
SA. There is a continuum of ISA from “modest ISA found at
outine IVUS follow-up,” as stated by Steinberg et al. (10), and
rank aneurysm formation, which has been associated with ST
16). In fact, in the study by Cook et al. (9), which found a high
revalence of ISA among consecutive patients with very late
T, the mean ISA area was extremely large (8.3  7.5 mm2)
nd nearly twice the minimum stent area of control subjects—
his was not subtle ISA like that found in many of the previous
tudies, which found no association between ISA and ST
6–8,11,12,14). In fact, the study by Cook et al. (9) was a
linical IVUS study investigating a high-risk group—very late
T—that is unlike many of the previously published studies,
ncluding the current publication, which reported only data
rom randomized trials requiring routine follow-up IVUS in
linically stable patients. Therefore, it is plausible that modest
SA (4 mm2) is less likely to be clinically relevant as opposedo more severe ISA, which seems to be more likely to result in
linical sequelae.
It seems unlikely that a definitive randomized trial or a large
nough observational registry will be performed that would
elp to determine whether ISA is clinically important. The
nfrequent nature of both ISA and ST, the need for routine
VUS follow-up, the long follow-up required to detect very late
T, and the exceedingly large number of patients required
eem prohibitive. It seems that, on the basis of the current
est-available published data, acute ISA is clinically unimpor-
ant, and the operator should focus on adequate stent expan-
ion, not synonymous with ISA, which has been consistently
ssociated with ST (2). Although plausible, there seems to be
o definitive evidence linking modest degrees of ISA, such as
eported by Steinberg et al. (10), and clinical events, namely
T. However, on the basis of limited observational evidence,
here does seem to be an association between more severe ISA
nd ST (9,16). Whether to treat either modest or severe ISA
y dilating the stent further remains unanswered. Obviously,
urther dilation of the stent carries minimal risk, and it might
itigate the future risk of ST.
Acute and late-acquired ISA is an IVUS phenomenon
hat is not definitively associated with adverse cardiovascular
vents, and until further exacting data are available, we
hould oppose the urge to appose routinely. The caveat to
his opposition position would be in cases with egregious
SA, which we believe is very likely to also be associated
ith stent underexpansion and thus ST.
eprint requests and correspondence: Dr. Steven P. Marso,
aint Luke’s Mid America Heart Institute, University of Missouri-
ansas City, 4401 Wornall Road, Kansas City, Missouri 64111.
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